MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Home・Elenco Azioni・Minerva Neurosciences Inc

Minerva Neurosciences Inc

Chiusa

2.49 -0.8

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.35

Massimo

2.51

Metriche Chiave
By Trading Economics
P/E Media del settore	1.625 36.442
EPS	-0.43
Dipendenti	8

Dividendi
By Dow Jones
Utili prossimi	3 nov 2025

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	4.9M 15M
Apertura precedente	3.29
Chiusura precedente	2.49

Minerva Neurosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 ott 2025, 18:13 UTC

I principali Market Mover

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17 ott 2025, 17:05 UTC

I principali Market Mover

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

17 ott 2025, 15:03 UTC

I principali Market Mover

Obook Shares Sink Following Public Debut

17 ott 2025, 14:41 UTC

I principali Market Mover

Disc Medicine Shares Surge After FDA Grants Priority Voucher for EPP Drug

17 ott 2025, 23:25 UTC

Acquisizioni, Fusioni, Takeovers

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 ott 2025, 22:15 UTC

Discorsi di Mercato

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 ott 2025, 21:15 UTC

Discorsi di Mercato

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17 ott 2025, 21:07 UTC

Discorsi di Mercato

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17 ott 2025, 21:07 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

17 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 ott 2025, 20:34 UTC

Discorsi di Mercato

Deere Is Reaching the End of Its Downcycle -- Market Talk

17 ott 2025, 20:27 UTC

Discorsi di Mercato

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17 ott 2025, 19:46 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17 ott 2025, 19:45 UTC

Discorsi di Mercato

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17 ott 2025, 18:45 UTC

Discorsi di Mercato

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17 ott 2025, 17:51 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 ott 2025, 17:51 UTC

Discorsi di Mercato

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17 ott 2025, 17:44 UTC

Discorsi di Mercato

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17 ott 2025, 17:35 UTC

Discorsi di Mercato

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17 ott 2025, 16:20 UTC

Discorsi di Mercato

Utili

Tech, Media & Telecom Roundup: Market Talk

17 ott 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 ott 2025, 16:14 UTC

Discorsi di Mercato

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17 ott 2025, 16:04 UTC

Discorsi di Mercato

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17 ott 2025, 15:58 UTC

Discorsi di Mercato

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17 ott 2025, 15:56 UTC

Utili

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17 ott 2025, 15:43 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

17 ott 2025, 15:43 UTC

Discorsi di Mercato

Amazon's Earnings Are About Sentiment of Consumers, Not Investors -- Market Talk

17 ott 2025, 14:58 UTC

Discorsi di Mercato

Small-Business Trepidation in Canada Points to Economic Decline -- Market Talk

17 ott 2025, 14:41 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 ott 2025, 14:35 UTC

Discorsi di Mercato

Utili

American Express's Delayed Card Fee Hike Worries Some Investors -- Market Talk

Confronto tra pari

Modifica del prezzo

Minerva Neurosciences Inc Previsione

Consenso sulla valutazione

By TipRanks

0 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 0 che hanno fornito valutazioni azionarie a Minerva Neurosciences Inc - Dist negli ultimi 3 mesi.

Notizie finanziarie

Chi Siamo Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.